Breaking

Nebius Shares Soar on US$17.4 Billion Microsoft AI Deal
Jaime Carrasco: Gold, Silver, Miners — Where to Focus in Monetary Storm
Gold and Silver Stocks Dominate TSX30 List of Top Performers
How to Invest in Medical Device Stocks and ETFs
Locksley Resources LimitedAdvances Antimony Supply Strategy
IR1:IR1 Completes Acquisition to Consolidate Black Hills, US
Exceptional result of 32m @ 7gt Au in Lord Byron drilling
Navigating Uncertainty: How to Manage Jurisdictional Risk for Mining Stocks

Home
Features
- View All On Demos
Buy Now
Search for:

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Nebius Shares Soar on US$17.4 Billion Microsoft AI Deal

September 10, 2025

Jaime Carrasco: Gold, Silver, Miners — Where to Focus in Monetary Storm

September 10, 2025

How to Invest in Medical Device Stocks and ETFs

September 10, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (234)
- Investing (1,018)
- Stocks (209)
- World (675)

Disclaimer: thecapitalstrategies.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2025 thecapitalstrategies.com | All Rights Reserved

Top

Type above and press Enter to search. Press Esc to cancel.